Skip to content
OpenCapital
Get started

Opus Genetics IRD Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value at other companies

Repligen logo
RepligenRGEN
$155.80—
AMN Healthcare logo
AMN HealthcareAMN
$80.79-9.9%
Kopin logo
KopinKOPN
$1.62—
Heartland Express logo
Heartland ExpressHTLD
$10.71-5.1%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$54.10+21.0%
Heartland Express logo
Heartland ExpressHTLD
$10.48-4.3%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?
Opus Genetics (IRD) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value of $1.31 in Q1 2026.
How has Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value changed year-over-year?
Opus Genetics's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value decreased by 31.4% year-over-year, from $1.91 to $1.31.